Takeda Pharmaceutical Company Ltd
🇸🇪Sweden
- Country
- 🇸🇪Sweden
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn's Disease
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 11
- Registration Number
- NCT02559713
- Locations
- 🇺🇸
Atlantic Health System, Morristown, New Jersey, United States
🇺🇸Feinberg School of Medicine Northwestern University, Chicago, Illinois, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
Phase 2 Study of TAK-850 in Comparison With Influenza Hemagglutinin (HA) Vaccine in Healthy Adult Participants
Phase 2
Completed
- Conditions
- Influenza Infection
- Interventions
- Biological: Influenza HA vaccineBiological: TAK-850
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2016-12-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 400
- Registration Number
- NCT02555618
A Single- and Multiple-Dose Study of the Pharmacokinetics of TAK-491 in Healthy Chinese Participants
Phase 1
Completed
- Conditions
- Healthy Volunteer
- Interventions
- Drug: TAK-491Drug: TAK-491 placebo
- First Posted Date
- 2015-09-04
- Last Posted Date
- 2020-02-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 64
- Registration Number
- NCT02541669
TAK-935 Multiple Rising Dose Study in Healthy Participants
Phase 1
Completed
- Conditions
- Epilepsy
- Interventions
- Drug: TAK-935Drug: Placebo
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 40
- Registration Number
- NCT02539134
Blood Sample Collection Study for Pharmacogenomic Characterization of Participants That Previously Received Namilumab in M1-1188-002-EM (PRIORA, [NCT01317797]) Study
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-08-19
- Last Posted Date
- 2018-01-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 8
- Registration Number
- NCT02528786
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of Trebananib (AMG 386 ) in Adult Japanese Participants With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Neoplasms, Advanced Solid
- Interventions
- First Posted Date
- 2015-08-17
- Last Posted Date
- 2015-09-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 18
- Registration Number
- NCT02525536
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
Phase 4
Completed
- Conditions
- Type 2 Diabetes MellitusEssential Hypertension
- Interventions
- First Posted Date
- 2015-08-07
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Takeda
- Target Recruit Count
- 380
- Registration Number
- NCT02517866
A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Disease
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Trelagliptin 25 mgDrug: Placebo
- First Posted Date
- 2015-07-30
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 107
- Registration Number
- NCT02512068
Phase 1 Bioavailability Study of SYR-322MET
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-07-24
- Last Posted Date
- 2016-10-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 24
- Registration Number
- NCT02508168
Phase 1, Febuxostat XR Relative Bioavailability Study
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Takeda
- Target Recruit Count
- 78
- Registration Number
- NCT02504320
© Copyright 2025. All Rights Reserved by MedPath